GALECTIN THERAPEUTICS INC. Restricted Cash and Cash Equivalents, Noncurrent
GALECTIN THERAPEUTICS INC. (GALT) had Restricted Cash and Cash Equivalents, Noncurrent of $6.00 thousand as of 2012-12-31, per its 10-K filed 2014-03-21.
Discontinued › Balance Sheet › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2014-03-21
- 2012-12-31: Restricted Cash and Cash Equivalents, Noncurrent $6.00K.
- 2012-06-30: Restricted Cash and Cash Equivalents, Noncurrent $69.00K.
- 2012-03-31: Restricted Cash and Cash Equivalents, Noncurrent $69.00K.
- 2011-12-31: Restricted Cash and Cash Equivalents, Noncurrent $69.00K.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2012-12-31 | $6.00K 10-K · filed 2014-03-21 |
| 2012-06-30 | $69.00K 10-Q · filed 2012-08-10 |
| 2012-03-31 | $69.00K 10-Q · filed 2012-05-11 |
| 2011-12-31 | $69.00K 10-K · filed 2013-03-29 |
| 2011-09-30 | $64.00K 10-Q · filed 2011-11-10 |
| 2011-06-30 | $64.00K 10-Q · filed 2011-08-12 |
| 2010-12-31 | $59.00K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |